MedPath

A clinical trial to compare the role of 14 days vs 21 days iv antibiotic in neonates with uncomplicated meningitis.

Phase 3
Conditions
Health Condition 1: G009- Bacterial meningitis, unspecified
Registration Number
CTRI/2023/06/053614
Lead Sponsor
Moti Lal Nehru Medical CollegePrayagraj
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

CSF proven Neonatal Meningitis

Exclusion Criteria

1.Presence of lethal chromosome abnormalities

2.Presence of severe congenital anomalies

3.Known immunodeficiency state

4.Symptomatic system congenital viral infection

5.Significant bleeding diathesis

6.Major intracranial bleed

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To compare the mortality or readmission of neonates with meningitis being <br/ ><br>treated with 14days vs 21 days antibiotic course in first 3 months of age. <br/ ><br>2.To look for recurrence of seizures or any complication for example ventriculitis, <br/ ><br>brain abscess, cerebral oedema, raised intracranial pressure, subdural empyema, <br/ ><br>hydrocephalus, infarct & sinus venous thrombosis post discharge from nicu.Timepoint: 3 months
Secondary Outcome Measures
NameTimeMethod
1.To cut off the unnecessary hospital stay in resource <br/ ><br>limited areas due to longer course of antibiotics <br/ ><br>2.To decrease the development of antimicrobial resistance. <br/ ><br>3.To prevent unwanted changes in flora form in NICU with optimal duration of <br/ ><br>empirical antibiotic . <br/ ><br>4.To decrease complication related to increased duration of antibiotic treatment <br/ ><br>such as Necrotising enterocolitis etc. <br/ ><br>5.Head circumference monitoring <br/ ><br>6.Weight monitoring <br/ ><br>7.Developmental milestones achievement status.Timepoint: 3 months
© Copyright 2025. All Rights Reserved by MedPath